Prof Brenchley is head of the renovascular biology research group in Cardiovascular Research. He directs the renal research labs and coordinates research for the Manchester Institute of Nephrology & Transplantation based at Manchester Royal Infirmary.
B.Sc. 1971; University of Birmingham
Ph.D. 1975; University of Manchester
The renovascular biology research group is concerned with translating knowledge gained from researching mechanisms of kidney disease and comorbidities into novel therapies for the benefit of patients. The group has interests in
a) preserving native kidney function and preventing progression of chronic kidney disease (CKD)
In this area we are investigating the nephrotic syndrome, in particular, mechanisms of proteinuria in Membranous Nephropathy, Minimal Change Disease and Focal Segmental Glomerular Sclerosis. We are researching the immune, inflammatory and epigenetic contribution to progression of chronic kidney disease through specific projects focused on Membranous Nephropathy, SLE nephritis and ANCA Vasculitis. We are developing novel biosensors for renal analytes that can detect patients at risk of chronic kidney disease.
b) improving dialysis modalities and reducing the comorbidities of dialysis
We are interested in developing novel ways of removing water and metabolic toxins in patients whose kidneys have failed. Arteriovenous fistulas (AVF) provide the vascular access necessary to undertake haemodialysis but 30-50% of AVF fail to mature following surgery. We are investigating the epigenetic, genetic and inflammatory mechanisms that control AVF maturation. For patients on peritoneal dialysis, it is essential that the peritoneal membrane maintains its function allowing water and uraemic toxins to be removed, but commonly the membrane can thicken over time due to fibrosis and permeability function is lost. A rare condition called encapsulating peritoneal sclerosis may develop in a minority of patients which is life threatening requiring surgery to remove a cocoon of fibrous matrix enveloping the viseral organs. We are researching the genetic and epigenetic mechanisms driving inflammatory scarring of the peritoneal membrane.
c) improving outcomes for kidney transplantation
The shortage of organs for transplantation means many patients cannot benefit from this therapy which for most patients is often the best form of renal replacement therapy. We are exploring stem cell based models for regenerating kidney tissue for transplantation and researching mechanisms that cause transplant kidneys to fail due to recurrence of the primary disease.